MedTrace Logo

Mechanism of EGR2 in Allergic Rhinitis

NCT05724290 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-02-13

No results posted yet for this study

Summary

EGR2 may be a target for the treatment of nasal polyps.

Conditions

  • Rhinitis, Allergic

Interventions

GENETIC

EGR2

We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Sponsors & Collaborators

  • Zu-xia Ma

    lead OTHER

Principal Investigators

  • Yong Luo, Doctor · Zunyi Medical College

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2023-02-01
Completion
2023-05-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05724290 on ClinicalTrials.gov